Stavudine News and Research

RSS
Stavudine, also known as Zerit or d4T, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). This class of medicines blocks reverse transcriptase, a protein that HIV needs to make more copies of itself. Stavudine was approved by the FDA on June 24, 1994, for use in combination with other antiretroviral agents for the treatment of HIV infection in adults and children. Stavudine may also be used to prevent health care workers and others from getting HIV infection after they accidentally come into contact with the virus on the job; however, this practice does not have FDA approval. Stavudine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Scientists create stem cell-based model of rare inherited neurological condition

Scientists create stem cell-based model of rare inherited neurological condition

Ethosomes may be effective carrier system for transdermal delivery

Ethosomes may be effective carrier system for transdermal delivery

Study highlights long-term benefits of early antiretroviral therapy initiated in infants

Study highlights long-term benefits of early antiretroviral therapy initiated in infants

Blog examines use of controversial HIV drug in Malawi

Blog examines use of controversial HIV drug in Malawi

AIDS battle: stretching use of anti-HIV drugs

AIDS battle: stretching use of anti-HIV drugs

Study reveals potential strength of different anti-HIV combination drugs

Study reveals potential strength of different anti-HIV combination drugs

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead, Mylan expand license deal for HIV/AIDS medicines

Gilead, Mylan expand license deal for HIV/AIDS medicines

Bristol-Myers Squibb and Mylan expand access to HIV drug Reyataz in sub-Saharan Africa and India

Bristol-Myers Squibb and Mylan expand access to HIV drug Reyataz in sub-Saharan Africa and India

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Earlier ART initiation should be highest priority for global expansion of HIV patient care

Earlier ART initiation should be highest priority for global expansion of HIV patient care

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

Switching to nevirapine drug from PI based regimen reduces viremia in children: Study

Switching to nevirapine drug from PI based regimen reduces viremia in children: Study

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Also in global health news: Kenya HIV/AIDS; Uganda bill; water project in Philippines; U.N. appeal for Yemen

Also in global health news: Kenya HIV/AIDS; Uganda bill; water project in Philippines; U.N. appeal for Yemen

WHO issues new HIV/AIDS treatment guidelines

WHO issues new HIV/AIDS treatment guidelines